is the most common type of malignant human cancer. It is caused by inherited or acquired defects in the regulation of normal homeostasis for a given epithelial cell population leading to enhanced and often uncontrolled growth at the expense of the host. There is good evidence to suggest that crosstalk between carcinoma epithelial cells and adjacent stromal cell populations may lead to selection of a tumor microenvironment that further promotes tumor progression. In human cancer, mutation including loss of heterozygosity (LOH) is a common feature associated with tumor progression and occurs in both the carcinoma epithelium and stroma from the tumor microenvironment. In this issue of Cell, Hill et al. (2005) show in a mouse model of prostate carcinoma that tumor cells induce upregulation of p53 through a paracrine mechanism in stromal fibroblasts. This process creates a selective pressure that promotes the expansion of a subpopulation of fibroblasts that lack p53. Stromal fibroblasts that lack p53 then contribute to tumor progression.
There In this issue of Cell, Hill et al. (2005) demonstrate in a mouse model of prostate cancer that the tumor cells can initiate and promote expansion of stromal fibroblasts that lack the tumor-suppressor protein p53 through a paracrine mechanism. This results in selection of highly proliferative fibroblasts associated with the carcinoma that further promote tumor progression.
Figure 1. The Carcinoma Epithelium Selects for p53 Null Stromal Fibroblasts
Expression of a fragment of the SV40 T antigen (TgAPT121) in the epithelium leads to suppression of retinoblastoma protein family members. Paracrine signaling by the epithelium then induces an upregulation in p53 expression in stromal fibroblasts, resulting in decreased fibroblast proliferation. Under this selective pressure, fibroblasts that have lost p53 are expanded. These carcinoma-associated fibroblasts contribute to tumor progression and the eventual loss of p53 in the epithelium. Multiple changes in stromal fibroblasts are known to contribute to tumor progression, including altered gene expression (for example, enhanced expression of SDF-1), loss of heterozygosity (for example, as frequently occur at 11q), and specific mutations (such as those that inactivate p53 or PTEN).
epithelial cell signaling, evidence indicated that carcinomas derived from transformed epithelial cells actually consisted of malignant epithelium in addition to permanently altered stromal fibroblast cell populations, known as carcinoma-associated fibroblasts.
The carcinoma-associated fibroblasts were shown to enhance tumorigenesis when cocultured with benign hyperplastic prostate epithelial cells. These early results indicated that fibroblasts isolated from primary tumors had acquired the ability to promote tumor progression in vivo (Hayward et al., 2001) . Van Dyke and colleagues (Hill et al., 2005) now use a mouse model of prostate cancer in which the retinoblastoma family of proteins are suppressed in the prostate epithelium by the expression of a fragment of the SV40 T antigen. They show that paracrine signaling by the epithelium induces upregulation of p53 expression in stromal fibroblasts, which results in decreased fibroblast proliferation (Figure 1 ). Under this selective pressure, fibroblasts that have lost p53 are able to expand. Thus, it appears that there is a selective evolution of a highly proliferative p53 null subpopulation of carcinoma-associated fibroblasts rather than induction of widespread p53 mutation in tumorassociated fibroblasts.
The p53 tumor-suppressor protein is frequently mutated in carcinoma cells. The inactivation of p53 can occur in the epithelium alone, stroma alone, or in both compartments of the carcinoma (Kurose et al., 2002) . The loss of p53 in fibroblasts induces tumor progression in adjacent epithelial cell populations (Kiaris et al., 2005) . Tumors form more rapidly in mice with severe combined immunodeficiency (SCID) that are injected with human mammary adenocarcinoma cells when the mice are p53 −/− compared to p53 +/− heterozygous or wild-type animals. Moreover, SCID mice that are wild-type for p53 develop tumors more rapidly when human breast cancer cells are mixed with p53 null mouse embryonic fibroblasts (MEFs) prior to injection than when they are mixed with MEFs that are wild-type for p53. These results indicate that p53 signaling in the stroma has a role in the regulation of tumor progression. Similarly, in the prostate cancer model used by Hill et al. (2005) , loss of p53 in fibroblasts precedes loss of p53 in the epithelium and may contribute to tumor progression.
Altered fibroblasts produce factors that promote tumorigenesis and enhance other processes, such as angiogenesis, that are required to promote and sustain cancer progression. Recently it was shown that fibroblasts isolated from human invasive ductal carcinoma can produce stromal cellderived factor 1 (SDF-1), a protein that both enhances growth of tumor epithelium and promotes angiogenesis through the recruitment of endothelial cells (Orimo et al., 2005) . In addition, loss of signaling through the type II transforming growth factor β receptor in fibroblasts enhances production of soluble factors, such as HGF, MSP, and TGF-α, that contribute to carcinoma initiation, proliferation, and migration while suppressing apoptosis in epithelial cells that express the respective receptors for these ligands (Bhowmick et al., 2004; Cheng et al., 2005) . These studies have helped to illustrate the interdependent signaling that controls the stromal-epithelial regulation of cancer.
Although the work of Hill et al. (2005) helps to explain the high frequency of p53 mutations in stromal cells associated with tumors, it is possible that this process could also select for stromal cells bearing many other mutations. A recent genome analysis of 134 sporadic invasive breast carcinomas revealed that the stromal components exhibited a higher number of genes preferentially lost due to LOH compared to the number lost due to LOH in the epithelium (Fukino et al., 2004) . It was reported that 38 markers were preferentially lost in the stroma, whereas 19 markers were preferentially lost in the epithelium. Because many of the markers representing hot spots for mutation in the stroma were not the same as those identified in the epithelium, it is likely that the stromal mutations were a result of independent mutation rather than divergence from a common progenitor (that is, through an epithelial-to-mesenchymal transition).
Evidence that genomic instability and mutation of individual cell populations in the tumor microenvironment is a regulated process comes from the statistical analysis of genomic markers and direct analysis of deleted chromosomal regions from each cell population. Mutations observed in the 11q chromosomal region illustrate how LOH can be differentially regulated. Six LOH hot-spot markers were identified in the 11q region within a 44 Mb span that is deleted in the epithelium and is flanked by 29 Mb and 11 Mb regions that are deleted in the stroma. The 44 Mbp region deleted in the epithelium notably contains the matrix metalloproteinase (MMP) gene cluster (Fukino et al., 2004) . The stage of tumor progression and distance from the primary tumor also impact the number of LOH events in the stroma (Moinfar et al., 2000) . Stromal components from human breast ductal carcinoma in situ exhibit less LOH than stromal components within infiltrating ductal carcinoma. There is also an association between the rate of LOH and the relative proximity of the stroma to a tumor mass (Moinfar et al., 2000) . Together, these results indicate that LOH in the tumor microenvironment is regulated in a cell-specific manner and that the rate of LOH depends on the stage of tumor progression and proximity of the stroma to the tumor mass. In addition to mutation and LOH, there are epigenetic changes in the tumor microenvironment that clearly influence tumor progression. Epigenetic modification of gene expression is also dependent on the proximity to the tumor mass, stage of progression, and cell type used for analysis (Hu et al., 2005) .
It is not known whether the selective pressure placed on stromal cells by the epithelium as described by Hill et al. (2005) occurs in all tumor microenvironments or whether the specific lineage of the fibroblast subpopulations (e.g., prostate fibroblasts versus mammary-gland fibroblasts) influences the ability to respond to this type of selective pressure. It will be instructive in future studies to compare the Cell 123, December 16, 2005 ©2005 Elsevier Inc. 987 current data of Hill et al. (2005) with those from other cancer models This should help to determine whether this newly described selective evolution of p53-deficient stroma is a general characteristic that can help to explain the prevalence of this and other common mutations in human cancer.
